Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Cetylpyridinium chloride study reanalysis shows antigingivitis effectiveness, P&G maintains.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

CETYLPYRIDINIUM CHLORIDE IS EFFECTIVE ANTIGINGIVITIS AGENT, P&G maintained in a presentation to the Dental Products Panel OTC Plaque Products Subcommittee on June 7. Based on a reanalysis of Procter & Gamble data previously presented to the subcommittee and on results of recent testing, P&G Senior Researcher Matthew Doyle, PhD, asserted that "when formulated correctly, CPC is an effective antigingivitis ingredient and therefore warrants Category I designation within the monograph."

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

PS085474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By